NGN-401, a novel gene therapy approach, aims to address the underlying genetic cause of RTT by delivering a functional copy of MECP2 using an adeno-associated virus (AAV) vector.
To read more, a subscription is needed: Click here to subscribe
NGN-401, a novel gene therapy approach, aims to address the underlying genetic cause of RTT by delivering a functional copy of MECP2 using an adeno-associated virus (AAV) vector.
To read more, a subscription is needed: Click here to subscribe 
Terms & Conditions | Privacy statement | Disclaimer | Site Credits
All rights reserved, including rights for text and data mining and training of artificial intelligence technologies or similar technologies.